Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
January 7, 2026 Off

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

By GlobeNewswire

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another…

January 7, 2026 Off

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

By GlobeNewswire

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease —  HONG KONG and…

January 7, 2026 Off

Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference

By GlobeNewswire

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative…

January 7, 2026 Off

ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

By GlobeNewswire

PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that…

January 7, 2026 Off

Alumis Announces Proposed Public Offering of Common Stock

By GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation…

January 7, 2026 Off

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

By GlobeNewswire

Conference call and webcast to be held at 8 a.m. ET on January 7, 2026BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE)…

January 7, 2026 Off

ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

By GlobeNewswire

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical…

January 6, 2026 Off

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

By GlobeNewswire

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the…

January 6, 2026 Off

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

By GlobeNewswire

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO,…

January 5, 2026 Off

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

By GlobeNewswire

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13)…

Posts pagination

Previous 1 … 22 23 24 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine